- Home
- NMRK vs VRDN Comparison
NMRK vs VRDN Comparison
Compare NMRK & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMRK | VRDN |
|---|---|---|
| Founded | 1929 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.1B |
| IPO Year | 2017 | 2014 |
Fundamental Metrics
Financial Performance| Metric | NMRK | VRDN |
|---|---|---|
| Price | $10.64 | $30.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 17 |
| Target Price | $16.75 | ★ $42.19 |
| AVG Volume (30 Days) | 2.2M | ★ 2.8M |
| Earning Date | 10-29-2026 | 11-04-2026 |
| Dividend Yield | ★ 2.21% | N/A |
| EPS Growth | ★ 100.00 | N/A |
| EPS | ★ 0.45 | N/A |
| Revenue | ★ $3,294,024,000.00 | $5,706,000.00 |
| Revenue This Year | $14.47 | $6.01 |
| Revenue Next Year | $4.78 | $316.34 |
| P/E Ratio | $24.13 | ★ N/A |
| Revenue Growth | ★ 20.29 | N/A |
| 52 Week Low | $10.84 | $13.18 |
| 52 Week High | $18.25 | $34.29 |
Technical Indicators
Market Signals| Indicator | NMRK | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 34.13 | 78.19 |
| Support Level | N/A | $17.84 |
| Resistance Level | $16.13 | $30.79 |
| Average True Range (ATR) | 0.52 | 1.51 |
| MACD | -0.05 | 0.51 |
| Stochastic Oscillator | 1.72 | 89.10 |
Price Performance
Historical ComparisonAbout NMRK Newmark Group Inc.
Newmark Group Inc is a commercial real estate advisory firm. It offers services, including leasing and corporate advisory services, investment sales, commercial mortgage brokerage, appraisal and valuation, project management, and property, among others. Newmark offers a diverse array of integrated services and products designed to meet the full needs of both real estate investors/owners and occupiers. The company provides real estate strategic consulting and systems integration services to CFI's clients including many Fortune and Forbes companies, owner-occupiers, government agencies, healthcare, and higher education clients.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.